Decision to open access to atomoxetine and change funded brand

PHARMAC

31 January 2019 - PHARMAC is pleased to announce that all funding restrictions on atomoxetine will be removed from 1 July 2019. 

PHARMAC will also be changing the funded brand of atomoxetine; Generic Partners’ brand will be listed from 1 July 2019; and, after a transition period the current brand Strattera will be delisted on 1 December 2019.

Read PHARMAC notification

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , New Zealand , Funding